Form 8-K - Current report:
SEC Accession No. 0001193125-26-305467
Filing Date
2026-07-16
Accepted
2026-07-16 08:38:12
Documents
15
Period of Report
2026-07-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20260714.htm   iXBRL 8-K 60642
2 EX-4.1 crdf-ex4_1.htm EX-4.1 163063
3 EX-4.2 crdf-ex4_2.htm EX-4.2 163587
4 EX-5.1 crdf-ex5_1.htm EX-5.1 33999
5 EX-10.1 crdf-ex10_1.htm EX-10.1 350337
6 EX-99.1 crdf-ex99_1.htm EX-99.1 31037
7 GRAPHIC img229051243_0.jpg GRAPHIC 12624
  Complete submission text file 0001193125-26-305467.txt   1047539

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20260714.xsd EX-101.SCH 23903
18 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20260714_htm.xml XML 4500
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 261178755
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)